Title: Evaluation of Treatment of Ear Lobe Keloid with Triamcinolone Injection and Surgical Excision
Authors: K. Aravinda Sagar, Kongara Rajesh, Amarendra Prasad N
DOI: http://dx.doi.org/10.18535/jmscr/v4i2.28
Abstract
The study includes 42 consecutive patients with 68 ear lobe keloids. Patients underwent local infiltration of triamcinolone acetonide (TCN) at concentrations of 40mg/ml (Group 1) and 20 mg/ml (Group 2). Different volume of TCN infiltrate according to the size of the lesion. Treatment consisted of three monthly injections before surgery, excision of keloid in the fourth month and perioperative infiltration, followed by two more infiltration of TCN within two months. Post-treatment follow-up of patients was done for12 months.
RESULTS:TCN at concentrations of 20mg/ml and 40mg/ml were effective for the treatment of keloids along with surgical excision,no difference between the groups (p = 0.73).
CONCLUSION:The combination of infiltration of TCN monthly (1.2mg to 2.0mg per mm3 ) and surgical excision is effective for treatment of ear lobe keloid .
KEY WORDS:Keloid; Triamcinolone Acetonide; Wound Healing; Surgical excision; Recurrence.
References
1. F. Charles Brunicardi,Dans K. Anderson, Timothy R. Billar,David L.Dunn, John G. Hunter, Jeffrey B.Mathews,Raphael E. Pollock: Schwartz’s principles of surgery: tenth edition:ch.9,wound healing, pg 261-64.
2. M. Townsend,Jr., R.Daniel Beauchamp, B.Mark Evers, Kenneth L. Mattox: Sabiston Textbook of surgery: The Biological Basis of Modern Surgical Practice, 19th edition, ch.7,wound healing, pg 164-66.
3. Urioste SS, Arndt KA, Dover JS. Keloidalscars and hypertrophic scars: review and treatment strategies. SeminCutan Med Surg.1999;18(2):159-71.
4. De Felice B, Ciarmiello LF, Mondola P, Damiano S, Seru R, Argenziano C, et al. Differential p63 and p53 expression in human keloid fibroblast and hypertrophic scar fibroblasts. DNA Cell Biol.2007;26(8):541-7.
5. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. PlastReconstr Surg. 1996;98 (5):827-33.
6. Ketchum LD, Robinson DW, Masters FW. Follow-up on treatment of hypertrophic scars and keloids with triamcinolone. PlastReconstr Surg.1971;48(3):256-9.
7. Babin RW, Ceilley RI. The freeze-injection method of hypertrophic scar and keloid reduction. Otolaryngol Head Neck Surg. 1979;87(6):911-4..
8. Shepherd JP, DawberRP.The response of keloid scars to cryosurgery.Plastic Reconstr Surg.1982;70(6):677-82.
9. Botwood N, Lewanski C, LowdellC. The risks of treating keloids with radiotherapy.Br J Radiol.1990;72(864):1222-4.
10. DarziMA,Chowdri NA, Kaul SK, Khan M. Evolution of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg. 1992;45(5):374-9.
11. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, Uitto J. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol. 1985; 121(5):632-5.
12. Shaffer JJ, TaylorSC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol.2002;46(2 Suppl Understanding): S63-97.
13. Griffith BH, Monroe CW, McKinney P.A follow-up study on the treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg. 1970;46(2):145-50.
14. Patterson DL, Yunginger JW, Dunn WF, Jones RT, Hunt LW. Anaphylaxis induced by carboxymethylcellulose component of injectable triamcinolone. Ann Allergy Asthma Immunol.1995;74(2):163-6.
15. TuanTL, NichterLS.The molecular basis of keloid an hypertrophic scar formation. Mol Med Today.1998;4(1):19-24.
16. Kim WJ. Cellular signaling in tissue regeneration. Yonsei Med J. 2000;41 (6):692-703.
17. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. 1999;43(2):179-84.